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Abstract
Background: Trastuzumab emtansine (Kadcyla®, T-DM1) is an antibody-drug conjugate used to treat HER2 (human
epidermal growth factor receptor 2) overexpressing metastatic breast cancer. In this report, we present the first case
of lacrimal drainage system stenosis identified after T-DM1 administration, and its successful treatment with a
topical steroid.
Case presentation: A 36-year-old female with metastatic breast cancer was referred for excessive tearing of both eyes.
She previously underwent mastectomy and was treated with multiple anti-cancer regimens. However, metastases to liver
and bone were identified and T-DM1 was administered. After 2 months, epiphora developed in both eyes and the
patient was referred for ophthalmologic examination. The height of the tear meniscus was increased. The fluorescein dye
disappearance test (FDDT) showed a delayed clearance in both eyes. Diagnostic lacrimal probing demonstrated a lower
distal canalicular stenosis in both eyes. Dacryocystography indicated multiple focal narrowing of nasolacrimal duct in the
right eye and diffused narrowing of nasolacrimal duct in the left eye. Topical eyedrop of tobramycin 0.3% and
dexamethasone 0.1% were prescribed four times a day. After 2 months of treatment, the patient reported relief from
epiphora, and the height of tear meniscus was normalized in both eyes.
Conclusion: T-DM1 administration in breast cancer treatment can induce lacrimal drainage system stenosis, which can be
treated effectively with a topical steroid.
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Background
Chemotherapeutic agents such as 5-fluorouracil, doce-
taxel, and S-1 induce nasolacrimal duct obstruction or
stenosis [1]. However, the ocular adverse effects of
targeted agents that are increasingly used in anti-cancer
treatment are relatively unknown.
Trastuzumab emtansine (Kadcyla®, T-DM1) is an anti-
body-drug conjugate consisting of trastuzumab
(targeting human epidermal growth factor receptor 2
(HER2)) and emtansine (microtubule-inhibitory agent,
DM-1). It selectively delivers DM-1 to HER2 overex-
pressing tumor cells resulting in prolonged survival of
patients with metastatic breast cancer, with reduced
toxicity profile [2]. The main adverse effects are non-
ocular; however, grade 1–2 ocular side effects such as
conjunctivitis, swollen tear duct, increased lacrimation
were reported in phase I/II clinical trials [3, 4]. Two case
reports with corneal lesion induced by T-DM1 were
published [5, 6], but no reports involving lacrimal drain-
age system have been presented so far. Herein, we report
a case of lacrimal drainage system stenosis after adminis-
tration of T-DM1 in advanced breast cancer.
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Case presentation
A 36-year-old female with metastatic breast cancer pre-
sented with complaints of epiphora involving both eyes.
She previously underwent skin-sparing mastectomy and
was treated with anti-cancer regimens including doce-
taxel/doxorubicin/cyclophosphamide combinations and
trastuzumab monotherapy. After local skin recurrence,
the regimen was changed to vinorelbine plus epirubicin
followed by a combination of capecitabine and lapatinib
for 39 months. New metastases to liver and bone were
found and T-DM1 was started. Two months after T-
DM1 administration, epiphora developed in both eyes
and the patient was referred for lacrimal system evalu-
ation. The patient’s uncorrected visual acuity was 20/10
in the right eye and 20/13 in the left eye. The height of
the tear meniscus was increased. The fluorescein dye
disappearance test (FDDT) showed a delayed clearance
in both eyes. The diagnostic lacrimal probing demon-
strated a lower distal canalicular stenosis in both eyes.
Dacryocystography showed multiple focal narrowing of
nasolacrimal duct in the right eye and a diffuse narrow-
ing of nasolacrimal duct in the left eye (Fig. 1). Topical
tobramycin 0.3% plus dexamethasone 0.1% was ad-
ministered four times a day during a month. After a
month-long treatment, the height of tear meniscus
was normalized in the right eye, but was slightly ele-
vated in the left eye. Therefore, a continuous use of
the eyedrop was recommended. After 2 months, she
reported relief from epiphora and the height of the
tear meniscus was normalized in both eyes (Fig. 2)
The FDDT also revealed effective clearance in both
eyes.
Discussion and conclusions
Unlike traditional chemotherapy, targeted therapy select-
ively blocks the growth of cancer cells rather than
attacking rapidly dividing cells. Ocular side effects in-
volving the lacrimal drainage system associated with
various chemotherapies are well documented; however,
little is known about targeted therapies.
The adverse effects of antibody-drug conjugates need
to be traced to the specific individual components, in
this case, emtansine and trastuzumab. Emtansine, a
derivative of maytansine, is attached to a monoclonal
antibody and enters the cells to inhibit microtubule
polymerization [7]. Ocular adverse effects of maytansine
family members have yet to be reported; however, the
nasolacrimal adverse effects of anti-neoplastic agents
with similar mechanism of action, such as docetaxel, are
well documented [8]. Docetaxel causes epiphora and
induces stenosis of lacrimal drainage system [9] and
stromal fibrosis in the mucosal lining of the affected lac-
rimal drainage system, and it has been confirmed by
histopathologic study [10]. Because emtansine and doce-
taxel share a similar mechanism of action, it can be as-
sumed that canalicular and nasolacrimal stenosis in our
patient might be due to the adverse effect of emtansine.
Two corneal lesions were reported as ocular adverse
effects of T-DM1 administration [5, 6] based on the ex-
pression of HER2 in corneal epithelial cells and its
Fig. 1 Dacryocystographic image of the patient showing multiple focal narrowing of nasolacrimal duct in right eye and diffuse narrowing of
nasolacrimal duct in left eye
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susceptibility to trastuzumab harboring agents. In litera-
ture, two studies have reported HER2 overexpression in
adenocarcinoma of lacrimal sac and nasolacrimal duct
[11, 12], but not in normal nasolacrimal epithelium. If
HER2 is also expressed in the normal nasolacrimal
epithelium, nasolacrimal stenosis in our case can be ex-
plained in part as an effect of trastuzumab. Future study
on the expression of HER2 in normal nasolacrimal sys-
tem is required to elucidate the pathophysiology [13].
T-DM1 shows a higher efficacy compared with trastuzu-
mab alone due to its dual effect on HER2 signaling and
cytotoxicity, also resulting in a higher intensity of adverse
effects. Ocular adverse effects were reported in 31.3% of T-
DM1 [4] compared with 2.5% following trastuzumab
monotherapy [14]. However, the comprehensive clinical
manifestations and prevalence of nasolacrimal adverse ef-
fects have yet to be reported. Severe epiphora causes not
only patient discomfort but also visual dysfunction. Future
study of its adverse effects on the nasolacrimal system is
certainly required.
Instillation of a topical steroid (combination of tobra-
mycin and dexamethasone) was effective in providing
symptomatic relief and quantitative decrease of tear me-
niscus in this case. In literature, a study reported a 61%
efficacy with topical steroids in nasolacrimal duct
obstruction [15]. Inflammation and edema of lacrimal
drainage are the main pathologic findings in the early
phase of lacrimal drainage system stenosis [16], which
can be reversed by anti-inflammatory treatments such as
topical steroids. Our group previously reported the ef-
fectiveness of topical steroid instillation in patients with
recent lacrimal drainage stenosis and cumulative im-
provement was found in 51% of the 108 eyes (63% of
cases with idiopathic nasolacrimal drainage stenosis,
100% of patients treated with docetaxel, and 43% of S-1-
treated patients) [17].
In our patient, the duration of epiphora was relatively
short and the onset was bilateral, simultaneous and con-
current with gradual exacerbation of symptoms after 2
months of T-DM1 treatment. Based on the previous
Fig. 2 Anterior segment optical coherence tomography showing increased height of tear meniscus on her first visit (OD 147 μm, OS 200 μm) in
(a) and decreased height of tear meniscus on follow up at 3 months (OD 100 μm, OS 154 μm) in (b)
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findings mentioned above, it is speculated that the
topical steroid was effective in controlling the inflamma-
tion and edema of nasolacrimal epithelium resulting in
symptom relief and decrease in tear meniscus. It is pos-
sible that the epiphora and lacrimal drainage stenosis in
this case were coincidental findings induced by other
etiologies and not T-DM1. However, no other possible
etiologies such as infection, endogenous or exogenous
inflammation, internal or external mechanical problem
or trauma were detected in previous history, symptoms
or signs of the physical examination or in radiological
tests and repeated blood labs. Although a direct cause-
effect relationship was not demonstrated, based on the
previous findings of pathological lacrimal drainage fol-
lowing anti-neoplasmic agents and exclusion of other
etiologies, we report that T-DM1 can be a cause of lacri-
mal drainage system stenosis. It also shows that early
diagnosis and treatment with topical steroid, which is
more accessible and low-cost than surgical intervention,
can reduce the burden of patients undergoing anti-can-
cer treatments.
Many studies have reported the adverse effects of che-
motherapeutic agents on the lacrimal drainage system;
however, those of targeted agents are less well known.
Prompt diagnosis and treatment in the early phase of
nasolacrimal obstruction can effectively decrease the
burden of patients undergoing systemic anti-cancer
treatments. Both oncologists and ophthalmologists need
to be better informed of such adverse effects for prompt
referral and effective early intervention.
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